ClinicalTrials.gg
RecruitingNCT06830382Updated Nov 20, 2025

HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC

An observational study in Breast Cancer Stage IV, HER2-low Breast Cancer and Molecular Imaging, sponsored by Renske Altena. Recruiting at 1 site in Sweden. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Renske Altena · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 252 studies in Breast Neoplasms with a site in Sweden — 56 open to participants now, 91 under way, 31 of them phase 3. Breast Neoplasms · Sweden.

Planned enrollment
39th of 42
70 · median 567
Started
2025
with 16 others
Observational
42 of 252
15 open now
Primary completion
2030-04
later than 81 of 90 live
Registered
233rd of 252
by date

Among the 252 studies in Breast Neoplasms with a site in Sweden, this one is the 39th largest by planned enrollment of the 42 observational ones that give a count, is one of 17 that started in 2025, is one of 42 observational ones, reaches primary completion later than 81 of the 90 other live ones, and was the 233rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

56 of the 252 studies in Breast Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Breast Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

This is a prospective, multi-center, open-label, exploratory diagnostic phase II imaging trial for patients with metastatic breast cancer with at least one line of systemic therapy.

The overarching aim of the HER2-Ex PET trial is to study the role of precision imaging utilizing positron emission tomography (PET) with the HER2-specific tracer [68Ga]Ga-ABY-025 (hereafter referred to as HER2-PET) in enhancing treatment planning for patients with metastatic HER2-expressing breast cancer Patients will be allocated based on HER2-status on PET and biopsy. Patients with HER2-expressing lesions in a fresh or archived tumour biopsy will be treated with T-DXd.

The study hypothesis is that PET/CT precision imaging with a contemporary HER2-radiotracer ([68Ga]Ga-ABY-025) can be used and can lead to a potentially better identification of patients who benefit from T-DXd treatment, thereby achieving improved treatment responses as well as fewer side effects. This study's diagnostic approach provides a more individualized treatment strategy. Additionally, this study can potentially give us a better biological understanding of HER2-expressing mBC.

Read the detailed description

The target population of the trial consists of female patients with mBC with known non-HER2-positive tumours or with unknown HER2-status. Patients can be included in the trial at the time of disease progression after at least one line of chemotherapy in the palliative setting, or within six months after completion of adjuvant therapy for primary breast cancer.

Patients will be recruited at the Breast Clinics of the Karolinska Comprehensive Cancer Center in Stockholm, the Uppsala Academic Hospital in Uppsala, and Skåne University hospital in Sweden. Additional study sites may be added during the conduct of the trial and after approval of the regulatory agencies. Patients can be referred for study-related investigations from other sites, but all study-related investigations will be performed at one of the three above-mentioned clinics.

Participants are eligible to participate in the study if they meet all the inclusion and none of the exclusion criteria listed below. Subject eligibility (that participants fulfil all inclusion criteria and do not meet any exclusion criteria) is established by the principal investigator or co- investigator that is involved in clinical care for the patient.

When an eligible patient decides to participate in the study, all screening- and treatment related procedures will be initiated no earlier than after the informed consent form is signed.

All patients will undergo a baseline study-specific HER2-PET and a tumour biopsy, the latter guided by the results from the HER2-PET. Lesions with sonographically feasible access and preferably with ABY-025 tracer uptake SUVmax ≥ 6 will be eligible for biopsy. In case no ABY-025 lesions are present or accessible for biopsy, a non-avid metastatic lesion is recommended for biopsy. For practical reasons, biopsies taken prior to the HER2-PET (no more than three months old and without exposition to systemic anti-cancer therapy or local radiotherapy to the specific lesion) can be used for study purpose.

Patients with HER2-expressing fresh or archived tumour biopsy will be treated with T-DXd.

A second HER2-PET will be done in all patients treated with T-DXd at the moment of treatment response evaluation after 9-12 weeks of treatment with T-DXd. An optional third HER2-PET and tumor biopsy will be done at the moment of disease progression on T-DXd.

03

Conditions studied

  • Breast Cancer Stage IV
  • HER2-low Breast Cancer
  • Molecular Imaging

Browse trials for

Keywords

  • HER2-PET
  • molecular imaging
  • precision imaging
  • HER2-low mBC
  • metastatic breast cancer
  • HER2-ADC
  • ABY-025
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with mBC considered for treatment with T-DXd.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients age ≥18 years.
  • or locally advanced breast cancer with disease progression after ≥ 1 in the palliative setting, or with disease relapse within six months after completion of (neo-) chemotherapy.
  • The patient must be able and willing to provide written consent to participate in the study.
  • At least one metastatic lesion ≥ 10 mm is available for

    o Exception can be made when a recent biopsy is available (no more than 12 months old and without exposition to -targeted therapy or local radiotherapy to the specific lesion).

  • At least one additional metastatic index lesion ≥ 10 mm for evaluation of treatment effect (according to v1.1)
  • ≤ 2.
  • Expected survival > 12 weeks.
  • : Females of must agree to use adequate contraception prior to study entry, for the duration of the study treatment phase and for six months after the last dose of [68Ga]Ga-ABY-025. Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone- releasing intrauterine devices (IUDs), and copper IUDs. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Women must refrain from donating eggs during this same period. Should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. If a female participant is of child-bearing potential (females are considered not of childbearing potential if they are at least one year and/or surgically sterile), she must have a documented negative serum Pregnancy testing prior to each administration of the IMP is obligatory.

Exclusion criteria

Exclusion Criteria:

  • for treatment for trastuzumab deruxtecan and inability to undergo this treatment as per local treatment routines.
  • A previously documented tumor that was -positive (IHC 3+ and/or HER2 gene amplification).
  • Other manifest except for basal cell carcinoma of the skin.
  • Inadequate cardiac, renal, bone marrow or liver function
  • Patients with increased risk of complications from biopsies, i.e. increased risk of bleeding, defined as

    • test (INR value) >1.4, count \<70 (109/l), activated partial thromboplastin time (APTT) >30s.
    • known bleeding disorders such as haemophilia, von Willebrand disease or platelet disorders.
    • any anticoagulants or antiplatelet treatment that cannot be temporarily paused
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Arm 1: HER2-expressing cohort

    Patients are allocated to arm 1 based on HER2-status in the tumor biopsy. Patients in arm 1 are treated - according to approved indications and the current standard of care - with trastuzumab deruxtecan. Patients in arm 1 will undergo a second PET after 3-4 treatment courses (9-12 weeks) and and optional third HER2-PET + tumor biopsy at the moment of disease progression.

    Diagnostic Test: Positron emission tomografy with [68Ga]Ga-ABY-025

  • Arm 2: HER2-zero cohort

    Patients with HER2-zero tumors (according to tumor biopsy) will be followed for possible AE's after the experimental investigation (HER2-PET) during two weeks after the investigation, and will thereafter go off study.

    Diagnostic Test: Positron emission tomografy with [68Ga]Ga-ABY-025

Interventions

  • Diagnostic testPositron emission tomografy with [68Ga]Ga-ABY-025

    Investigational Medicinal product (IMP):\[68Ga\]Ga-ABY-025 (all patients)

This study also gives Trastuzumab deruxtecanStudies of Trastuzumab deruxtecanTrastuzumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Therapy-predictive role of HER2-PET for the clinical benefit of treatment with T-DXd in patients with HER2-expressing mBC

    The primary endpoint is the correlation between the mean \[68Ga \]Ga-ABY-025 SUVmax in the five most ABY-025 avid lesions at the baseline HER2-PET and treatment response according to RECIST v1.1 after three-four cycles of treatment with T-DXd.

    Time frame: 9-12 weeks (first response evaluation)

Secondary outcomes

  1. Changes in HER2-status according to [68Ga]Ga-ABY-025 uptake prior to and after 3-4 cycles of treatment with T-DXd

    Changes (deltaSUVmax) in HER2-status in up to five target lesions according to \[68Ga \]Ga-ABY-025 uptake prior to and after 3-4 cycles of treatment with T-DXd.

    Time frame: 9-12 weeks (first response evaluation)

  2. Correlation between the proportion of HER2-avid metastases in relation to the total burden of disease (lesions ≥10 mm) on CT and treatment response.

    Correlation between HER2-expressing total tumor volume (HER2-TTV; defined as proportion of ABY-025 avid lesions in relation to the total tumor volume (TTV, lesions ≥10 mm) defined on CT) at baseline and Overall Response Rate.

    Time frame: 12 months

  3. Health related quality of life at baseline, the first response evaluation and at disease progression.

    Change in patient reported Health-Related Quality of Life (HR-QoL) as measured by the EQ-5D-5L questionnaire from baseline to the first treatment evaluation.

    Time frame: 9-12 weeks (first response evaluation)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Altena R, Wiklander OPB, Romdhani NS, Kistner A, Klintman M, Skarping I, Lindman H, Rodriguez VS, Frisell O, Lindgren P, Bratteby K, Jussing E, Feldwisch J, Frejd FY, Cascales HS, Siikanen J, Hindorf C, Tran TA. HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial. Front Oncol. 2026 Apr 10;16:1812711. doi: 10.3389/fonc.2026.1812711. eCollection 2026. PubMed 42038396 ↗

Individual participant data

Plan to share: Undecided — IPD will be shared upon a reasonable request to the study sponsor representative and study director.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Apr 2030, 53 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 53 months is close to that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 17, 2025
StartActual
Oct 3, 2025
Primary completionEst.
Apr 1, 2030
CompletionEst.
Apr 1, 2032
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830382
Lead sponsor
Renske Altena
Collaborators
Karolinska Institutet, Affibody
Responsible party
Renske Altena (Study Director, Karolinska University Hospital) — Sponsor-investigator
First posted
Feb 17, 2025
Start date
Oct 3, 2025
Primary completion
Apr 1, 2030 (estimated)
Completion
Apr 1, 2032 (estimated)
Last update
Nov 20, 2025

Study contacts

Thuy Tran, Associate Prof, PharmD, PhD
Contact
thuy.tran@regionstockholm.se
+46812377777
Renske Altena, Associate Professor, MD PhD
Contact
renske.altena@ki.se
Renske Altena, MD PhD
study director · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion